InvestorsHub Logo

blue finch

12/16/22 10:31 AM

#392737 RE: JKS3 #392736

That's true. And given all the problems it's a much better estimate

But hey it's better than bankruptcy

Mikesc

12/16/22 12:26 PM

#392781 RE: JKS3 #392736

what are you smoking today?

bas2020

12/16/22 12:47 PM

#392790 RE: JKS3 #392736

Well... No company has ever delivered amazing results as this in an AD trial... we're not just talking slower decline. No, we're talking IMPROVEMENTS in patient's health, mood, sleep and daily living.

That's worth 10s of $Billions upfront!

nor377

12/16/22 1:58 PM

#392825 RE: JKS3 #392736

Below you can see three licensing deals by Biogen that had much larger up front payments:
From Fierce Bio JPM Week
That said, all three of Biogen's deals—with Sage, Sangamo and Denali Therapeutics, worth around $8 billion altogether—are high risk, too, given the challenges of operating in neurosciences. A hefty $2.8 billion of that total was paid upfront.